# US 2026/0125462 A1 · Compounds and methods targeting interleukin-19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125462 A1
- Document ID: US20260125462A1
- Status: Published application
- Kind: A1
- Application number: 19/323,384
- Filed: 2025-09-09
- Published: 2026-05-07
- Earliest claimed: 2018-01-17
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Richard Earl HIGGS, JR.; Robert John KONRAD; Brian Jeffrey NICKOLOFF; Robert William SIEGEL, II
- Web page: https://patentgrep.com/patent/US20260125462A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6869: {Interleukin}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- G01N 2333/54: Interleukins [IL]
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/202: Dermatitis
- G01N 2800/205: Scaling palpular diseases, e.g. psoriasis, pytiriasis
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.

## Claims

### Claim 1

An antibody which binds to human IL-19, said antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3 selected from:
a. a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 having at least 95% amino acid sequence homology to the amino acid sequence of a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 1;
b. grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 having at least 95% amino acid sequence homology to the amino acid sequence of a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 2; or
c. grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 having at least 95% amino acid sequence homology to the amino acid sequence of a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 3.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein LCDR1, LCDR2, LCDR3, HCDR1, HCDR2 and HCDR3 are selected from:
a. a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 1 and having the amino acid sequence of the grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 1;
b. a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 2 and having the amino acid sequence of the grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 2; or
c. a grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 3 and having the amino acid sequence of the grouping of LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 provided in Table 3.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the LCVR and the HCVR are selected from:
a. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 66 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 70;
b. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 74 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 78;
c. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 82 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 86;
d. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 34 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 38;
c. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 42 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 46;
f. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 50 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 54;
g. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 58 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 62;
h. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 294 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 298; and
i. the LCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 302 and the HCVR having an amino acid sequence with at least 95% homology to the amino acid sequence of SEQ ID NO: 306.

### Claim 4 (depends on 2)

The antibody of claim 2, wherein LCVR and HCVR are selected from:
a. the LCVR having the amino acid sequence of SEQ ID NO: 66 and the HCVR having the amino acid sequence of SEQ ID NO: 70;
b. the LCVR having the amino acid sequence of SEQ ID NO: 74 and the HCVR having the amino acid sequence of SEQ ID NO: 78;
c. the LCVR having the amino acid sequence of SEQ ID NO: 82 and the HCVR having the amino acid sequence of SEQ ID NO: 86;
d. the LCVR having the amino acid sequence of SEQ ID NO: 34 and the HCVR having the amino acid sequence of SEQ ID NO: 38;
e. the LCVR having the amino acid sequence of SEQ ID NO: 42 and the HCVR having the amino acid sequence of SEQ ID NO: 46;
f. the LCVR having the amino acid sequence of SEQ ID NO: 50 and the HCVR having the amino acid sequence of SEQ ID NO: 54;
g. the LCVR having the amino acid sequence of SEQ ID NO: 58 and the HCVR having the amino acid sequence of SEQ ID NO: 62;
h. the LCVR having the amino acid sequence of SEQ ID NO: 294 and the HCVR having the amino acid sequence of SEQ ID NO: 298; and
i. the LCVR having the amino acid sequence of SEQ ID NO: 302 and the HCVR having the amino acid sequence of SEQ ID NO: 306.

### Claim 5 (depends on 1)

The antibody of claim 1 further comprising a IgG1 heavy chain.

### Claim 6 (depends on 1)

The antibody of claim 1 further comprising a kappa light chain.

### Claim 7 (depends on 1)

A method of treating an immune-mediated disease comprising administering to a patient in need thereof an effective amount of an antibody of claim 1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the immune-mediated disease is one of: PsO, AD, PsA and renal nephropathy.
